10 results on '"Chun-Guang Qiu"'
Search Results
2. Correlating blood levels of 8-hydroxydeoxyguanosine to hOGG1 genotypes and the incidence of ischemic cardiomyopathy
- Author
-
Yu Jin, Chun-Guang Qiu, Qiang-Sun Zheng, Shi-Fang Ding, and Qi-Jun Jiang
- Subjects
8-hydroxy guanine glycosylase ,8-hydroxy-deoxyguanosine ,Ischemic cardiomyopathy ,Oxidative stress ,Polymorphism ,Medicine (General) ,R5-920 - Abstract
We measured the serum levels of 8-hydroxydeoxyguanosine (8-OHdG) and investigated whether these levels correlate with incidence of ischemic cardiomyopathy (ICM), and whether these levels correlate with underlying oxidative stress in patients with ICM. Polymerase chain reaction-restriction fragment length polymorphism analysis was performed to assess the prevalence of the Ser/Cys polymorphism in the human 8-oxoguanine glycosylase (hOGG1) gene. We analyzed the samples from 246 ICM cases (the ICM group) and another 246 age- and sex-matched volunteers with normal coronary artery function (the control group). Levels of 8-OHdG in participants' blood samples were 6.7 ± 1.7 and 3.0 ± 0.8 in the ICM and control groups, respectively (p
- Published
- 2016
- Full Text
- View/download PDF
3. Drug-coated balloons for the treatment of ostial left anterior descending or ostial left circumflex artery lesions: a patientlevel propensity score-matched analysis.
- Author
-
Liang PAN, Wen-Jie LU, Zhan-Ying HAN, San-Cong PAN, Xi WANG, Ying-Guang SHAN, Meng PENG, Xiao-Fei QIN, Guo-Ju SUN, Pei-Sheng ZHANG, Jian-Zeng DONG, and Chun-Guang QIU
- Subjects
TRANSLUMINAL angioplasty ,CARDIOVASCULAR system physiology ,CONFIDENCE intervals ,DRUG-eluting stents ,SURGICAL stents ,MEDICAL care ,RETROSPECTIVE studies ,MYOCARDIAL infarction ,CARDIOVASCULAR system ,COMPARATIVE studies ,CORONARY artery disease ,DESCRIPTIVE statistics ,SENSITIVITY & specificity (Statistics) ,ODDS ratio - Abstract
BACKGROUND Controversy exists as to the optimal treatment approach for ostial left anterior descending (LAD) or ostial left circumflex artery (LCx) lesions. Drug-coated balloons (DCB) may overcome some of the limitations of drug-eluting stents (DES). Therefore, we investigated the security and feasibility of the DCB policy in patients with ostial LAD or ostial LCx lesions, and compared it with the conventional DES-only strategy. METHODS We retrospectively enrolled patients with de novo ostial lesions in the LAD or LCx who underwent interventional treatment. They were categorized into two groups based on their treatment approach: the DCB group and the DES group. The treatment strategies in the DCB group involved the use of either DCB-only or hybrid strategies, whereas the DES group utilized crossover or precise stenting techniques. Two-year target lesion revascularization was the primary endpoint, while the rates of major adverse cardiovascular events, cardiac death, target vessel myocardial infarction, and vessel thrombosis were the secondary endpoints. Using propensity score matching, we assembled a cohort with comparable baseline characteristics. To ensure result analysis reliability, we conducted sensitivity analyses, including interaction, and stratified analyses. RESULTS Among the 397 eligible patients, 6.25% of patients who were planned to undergo DCB underwent DES. A total of 108 patients in each group had comparable propensity scores and were included in the analysis. Two-year target lesion revascularization occurred in 5 patients (4.90%) and 16 patients (16.33%) in the DCB group and the DES group, respectively (odds ratio = 0.264, 95% CI: 0.093-0.752, P = 0.008). Compared with the DES group, the DCB group demonstrated a lower major adverse cardiovascular events rate (7.84% vs. 19.39%, P = 0.017). However, differences with regard to cardiac death, non-periprocedural target vessel myocardial infarction, and definite or probable vessel thrombosis between the groups were non-significant. CONCLUSIONS The utilization of the DCB approach signifies an innovative and discretionary strategy for managing isolated ostial lesions in the LAD or LCx. Nevertheless, a future randomized trial investigating the feasibility and safety of DCB compared to the DES-only strategy specifically for de novo ostial lesions in the LAD or LCx is highly warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. An insurance contract with a low compensation period under adverse selection.
- Author
-
Ben-jiang Ma, Chun-guang Qiu, and Wen-Jie Bi
- Published
- 2015
- Full Text
- View/download PDF
5. Stentless at ostium: a novel approach for treating ostial left anterior descending or left circumflex coronary artery lesions with drug-coated balloons
- Author
-
Wen-Jie, Lu, Liang, Pan, Zhan-Ying, Han, San-Cong, Pan, Xi, Wang, Ying-Guang, Shan, Meng, Peng, Xiao-Fei, Qin, Guo-Ju, Sun, Pei-Sheng, Zhang, Jian-Zeng, Dong, and Chun-Guang, Qiu
- Subjects
Original Article - Abstract
Background: Currently, there is no optimal treatment strategy for ostial left anterior descending (LAD) or ostial left circumflex artery (LCx) lesions. This study explored effectiveness and safety of drug-coated balloons (DCB) in individuals presenting with ostial LAD or LCx lesions. Methods: A total of 137 patients with de novo ostial LAD or LCx lesions scheduled for DCB treatment were prospectively recruited into the study. After mandatory lesion preparation, DCB-only or hybrid strategy [DCB + drug-eluting stent (DES)] were performed on 120 patients (87.59%). The primary endpoint was the rate of 2-year target lesion revascularization (TLR). Rates of major adverse cardiovascular events (MACE), cardiac death, target vessel myocardial infarction (TVMI), and vessel thrombosis were explored as the secondary outcomes. Quantitative coronary angiography software was used to analyze coronary angiograms. Results: Of the participants, 58 were treated with DCB-only and 62 with hybrid strategy. Relative to the DCB-only group, patients in the hybrid group had longer target lesions (15.47 ± 10.08 vs. 36.85 ± 9.46 mm, P 0.05). Treatment strategy (DCB-only or hybrid) was not a significant risk factor for TLR. Patients who underwent DCB-only exhibited less late lumen loss compared with the patients who underwent hybrid strategy (-0.26 ± 0.59 vs. 0.42 ± 0.47 mm, P
- Published
- 2022
6. Rationale and design for comparison of non-compliant balloon with drug-coating balloon angioplasty for side branch after provisional stenting for patients with true coronary bifurcation lesions: a prospective, multicentre and randomised DCB-BIF trial
- Author
-
Xiao-Fei Gao, Zhen Ge, Jing Kan, Xiang-Quan Kong, Yan Wang, Chun-Guang Qiu, Damras Tresukosol, Yu-Quan He, Qiang Wu, Ji-Fu Li, Hai-Tao Yuan, Chengxing Shen, Xiang Chen, Muhammad Munawar, Bashir Hanif, Teguh Santoso, Eun-Seok Shin, Imad Sheiban, Fei Ye, Jun-Jie Zhang, and Shao-Liang Chen
- Subjects
Coronary Restenosis ,Treatment Outcome ,Coronary Stenosis ,Myocardial Infarction ,Humans ,Drug-Eluting Stents ,Stents ,Coronary Artery Disease ,Prospective Studies ,General Medicine ,Angioplasty, Balloon, Coronary ,Coronary Angiography - Abstract
IntroductionProvisional stenting using drug-eluting stent is effective for simple coronary bifurcation lesions. Kissing balloon inflation using conventional non-compliant balloon is the primary treatment of side branch (SB) after main vessel (MV) stenting. Drug-coating balloon (DCB) is reported to be associated with less frequent clinical events in in-stent restenosis and small vessel disease. The importance of DCB in bifurcation treatment is understudied. Accordingly, this trial is designed to investigate the superiority of DCB to non-compliant balloon angioplasty for SB after provisional stenting in patients with true coronary bifurcation lesions.Methods and analysisThe DCB-BIF trial is a prospective, multicentre, randomised, superiority trial including 784 patients with true coronary bifurcation lesions. Patients will be randomised in a 1:1 fashion to receive either DCB or non-compliant balloon angioplasty if SB diameter stenosis >70% after MV stenting. The primary endpoint is the composite of major adverse cardiac event at the 1-year follow-up, including cardiac death, myocardial infarction (MI) or clinically driven target lesion revascularisation. The major secondary endpoints include all-cause death, periprocedural MI, spontaneous MI, clinically driven target vessel revascularisation, in-stent restenosis, stroke and individual component of the primary endpoint. The safety endpoint is the risk of stent thrombosis.Ethics and disseminationThe study protocol and informed consent have been reviewed and approved by the Institutional Review Board of all participating centres. The written informed consent for participation in the trial will be obtained from all participants. The results of this study will be published in a peer-reviewed journal and disseminated at conferences.Trial registration numberNCT04242134.
- Published
- 2022
7. Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure
- Author
-
Kui-Po Yan, Chun-Guang Qiu, Li Ming, Liu Xincan, Wei Wang, Chao Li, and Chen Lei
- Subjects
0301 basic medicine ,Cardiac function curve ,Male ,MAP Kinase Signaling System ,p38 mitogen-activated protein kinases ,Apoptosis ,Smad Proteins ,p38 Mitogen-Activated Protein Kinases ,Transforming Growth Factor beta1 ,03 medical and health sciences ,Mice ,In vivo ,Drug Discovery ,medicine ,Animals ,Doxorubicin ,Antihypertensive Agents ,Cells, Cultured ,Heart Failure ,Chemistry ,Organic Chemistry ,In vitro ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,Terminal deoxynucleotidyl transferase ,Cancer research ,Molecular Medicine ,Valsartan ,RNA, Long Noncoding ,medicine.drug ,Transforming growth factor - Abstract
This study investigated the interaction among valsartan (VAL), TGF-β pathways, and long non-coding RNA (lncRNA) cardiac hypertrophy-related factor (CHRF) in doxorubicin (DOX)-induced heart failure (HF), and explored their roles in DOX-induced HF progression. HF mice models in vivo were constructed by DOX induction. The expression of CHRF and TGF-β1 in hearts was detected, along with cardiac function, caspase-3 activity, and cell apoptosis. Primary myocardial cells were pretreated with VAL, followed by DOX induction in vitro for functional studies, including the detection of cell apoptosis with terminal deoxynucleotidyl transferase dUTP nick-end labeling and the expression of proteins associated with TGF-β1 pathways. HF models were established in vivo and in vitro. Expression of CHRF and TGF-β1 was up-regulated, and cell apoptosis and caspase-3 activity were increased in the hearts and cells of the HF models. VAL supplementation alleviated the cardiac dysfunction and injury in the HF process. Moreover, overexpressed CHRF up-regulated TGF-β1, promoted myocardial cell apoptosis, and reversed VAL’s cardiac protective effect, while interference of CHRF (si-CHRF) did the opposite. Down-regulation of CHRF reversed the increased expression of TGF-β1 and the downstream proteins induced by pcDNA-TGF-β1 in HL-1 cells, while overexpression of CHRF reversed the VAL’s cardiac protective effect in vivo. In conclusion, VAL regulates TGF-β pathways through lncRNA CHRF to improve DOX-induced HF.
- Published
- 2017
8. The association between an endothelial nitric oxide synthase gene polymorphism and coronary heart disease in young people and the underlying mechanism
- Author
-
Chun‑Guang Qiu, Hai‑Long Tao, Ying‑Wei Chen, Shu‑Min Ren, Xiao‑Jie Chen, Xiangdong Kong, J Z Dong, Jha Sarbesh, and He‑Ping Gu
- Subjects
0301 basic medicine ,Male ,Protein Conformation, alpha-Helical ,Cancer Research ,Candidate gene ,Gene Expression ,Coronary Disease ,030204 cardiovascular system & hematology ,Biochemistry ,chemistry.chemical_compound ,0302 clinical medicine ,Gene Frequency ,Enos ,Risk Factors ,Catalytic Domain ,Genotype ,biology ,Oncology ,Molecular Medicine ,Female ,Polymorphism, Restriction Fragment Length ,Adult ,medicine.medical_specialty ,Adolescent ,Nitric Oxide Synthase Type III ,Polymorphism, Single Nucleotide ,Nitric oxide ,03 medical and health sciences ,Internal medicine ,Genetics ,medicine ,Humans ,Genetic Predisposition to Disease ,Protein Interaction Domains and Motifs ,Molecular Biology ,Gene ,Allele frequency ,Alleles ,business.industry ,Computational Biology ,biology.organism_classification ,Genotype frequency ,Protein Structure, Tertiary ,030104 developmental biology ,Endocrinology ,chemistry ,Amino Acid Substitution ,Haplotypes ,Case-Control Studies ,Protein Conformation, beta-Strand ,Gene polymorphism ,business - Abstract
With the development of molecular biological technology, the association between genes and diseases has drawn increasing attention of researchers; the endothelial nitric oxide synthase (eNOS) gene has been reported to be a candidate gene for cardiovascular disease (CHD). The present study aimed to investigate the association between a polymorphism of eNOS and the risk of CHD in young people (≤40 years old), in addition to the underlying mechanism. A total of 234 cases of CHD in young individuals were collected as the CHD group and 228 cases of healthy individuals as the control group. Peripheral blood was collected and the genotype of the eNOS G894T polymorphism was identified by polymerase chain reaction-restriction fragment length polymorphism, the gene frequency was calculated and the distributions of genotype and allele frequency between the two groups were compared. Bioinformatics tools were employed to analyze the differences in the local protein structures of the eNOS G894T polymorphism and the biological mechanism was preliminary discussed. The results demonstrated that there were significant differences in the distribution of genotype frequency and allele frequency of the eNOS G894T gene polymorphism between the CHD group and control group (P
- Published
- 2017
9. Association of dietary vitamin E intake with risk of lung cancer: a dose-response meta-analysis
- Author
-
Yong-Jian, Zhu, Ya-Cong, Bo, Xin-Xin, Liu, and Chun-Guang, Qiu
- Subjects
Male ,Risk ,Lung Neoplasms ,Dose-Response Relationship, Drug ,Humans ,Vitamin E ,Diet - Abstract
Several epidemiological studies investigating the association between dietary vitamin E intake and the risk of lung cancer have demonstrated inconsistent results. Hence, a meta-analysis was conducted to summarise evidence of the association of dietary vitamin E intake with the risk of lung cancer.In this meta-analysis, a systematic literature search of PubMed and Web of Science was conducted to identify relevant studies published from 1955 to April 2015. If p0.05 or I250%, a random effect model was used to estimate overall relative risks (RRs) and 95% confidence intervals (CIs). Otherwise, a fixed effect model was applied. Publication bias was estimated using the funnel plot and Egger's test. The doseresponse relationship was assessed using the method of restricted cubic splines with 4 knots at percentiles 5, 35, 65, and 95 of the distribution.The pooled RR of lung cancer for the highest versus lowest categories of dietary vitamin E intake was 0.84 (95% CI=0.76-0.93). With every 2 mg/d increase in dietary vitamin E intake, the risk of lung cancer statistically decreased by 5% (RR=0.95, 95% CI =0.91-0.99, plinearity=0.0237).Our analysis suggests that higher dietary vitamin E intake exerts a protective effect against lung cancer.
- Published
- 2017
10. Chinese experts recommendation on the monitoring and management of variability in responsiveness to antiplatelet therapy
- Author
-
Association, Chinese Society of Cardiology of Chinese Medical, Association, Chinese Society of Cardiology of Chinese Medical, Yong, Huo, Ya-Ling, Han, Run-Lin, Gao, Da-Yi, Hu, Yun, Zhang, Jun-Bo, Ge, Yong-Qiang, Zhao, Xu-Bo, Shi, Yi-Da, Tang, Zhen-Yu, Liu, Jing-Bo, Hou, Feng, Bai, Ji-Yan, Chen, Shao-Liang, Chen, Yun-Dai, Chen, Hong-Liang, Cong, Zhi-Min, Du, Wei-Yi, Fang, Guo-Sheng, Fu, Xiang-Hua, Fu, Chuan-Yu, Gao, Run-Lin, Gao, Wei, Gao, Jun-Bo, Ge, Lei, Ge, Li-Jun, Guo, Ya-Ling, Han, Ben, He, Jing-Bo, Hou, Da-Yi, Hu, Yong, Huo, Fu-Sui, Ji, Da-Lin, Jia, Guo-Liang, Jia, Shao-Bin, Jia, Xue-Jun, Jiang, Quan-Min, Jing, Bao, Li, Chun-Jian, Li, Guo-Qing, Li, Hong-Wei, Li, Jian-Ping, Li, Lang, Li, Xiao-Ying, Li, Xiao-Dong, Li, Yi, Li, Yong-Jun, Li, Chun, Liang, Bin, Liu, Jun-Ming, Liu, Qi-Ming, Liu, Zhen-Yu, Liu, Shu-Zheng, Lv, Gen-Shan, Ma, Li-Kun, Ma, Yi-Tong, Ma, Shao-Ping, Nie, Jian-Jun, Peng, Shu-Bin, Qiao, Chun-Guang, Qiu, Wei-Feng, Shen, Zhu-Jun, Shen, Xu-Bo, Shi, Fu-Cheng, Sun, Yi-Hong, Sun, Yi-Da, Tang, Ye, Tian, Chun-Xue, Wang, Hai-Chang, Wang, Jian-An, Wang, Le-Feng, Wang, Wei-Min, Wang, Chang-Qian, Wang, Meng, Wei, Shang-Yu, Wen, Yong-Jian, Wu, Ya-Wei, Xu, Hong-Bing, Yan, Li-Xia, Yang, Tian-He, Yang, Yue-Jin, Yang, Bo, Yu, Jin-Qing, Yuan, Zu-Yi, Yuan, Qi, Zhang, Rui-Yan, Zhang, Shu-Yang, Zhang, Yun, Zhang, Zheng, Zhang, Xue-Zhong, Zhao, Yong-Qiang, Zhao, Xu-Chen, Zhou, Yu-Jie, Zhou, Jian-Hua, Zhu, and Jun, Zhu
- Abstract
Antiplatelet agents are widely used in patients with coronary artery disease for the prevention of thrombotic events. However, individual responsiveness to antiplatelet agents is greatly varied, which is deemed as one of the most important risk factors for adverse clinic events, such as thrombosis and bleeding. Although studies on this aspect have lasted for more than a decade, the appropriateness of responsiveness variability monitoring and management for antiplatelet treatment remains controversial. Based on current clinical evidence, expert recommendations by a working group of Chinese Society of Cardiology of Chinese Medical Association were released focused on the methodology, clinical interpretation, and appropriateness of antiplatelet responsiveness variability monitoring and management.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.